NCT00146744View on ClinicalTrials.gov

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions

Tuberculosis (TB)

Interventions

BIOLOGICAL

Mtb72F/AS02A

Trial Locations (1)

1011

GSK Investigational Site, Lausanne

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY